ESTRO 2024 - Abstract Book

S1034

Clinical - Gynaecology

ESTRO 2024

Results:

Between 2017 and 2023, 87 patients were analysed with a median follow-up of 36 months.

52 out of 87 (60%) of patients presented with low Hb (< 120 g/l). All patients with Hb ≤ 120 were transfused packed red blood cells (PRBC) either before or at start of RT. Hb was monitored weekly and repeat transfusions were organised when either symptomatic of anaemia or Hb < 120 g/l.

For the purpose of results, we classified the patients into four groups according to Hb (g/l).

Group A: Hb <100 (8/87); Group B: Hb 100-110 (12/87); Group C: Hb 111-120 (18/87) and Group D Hb >120 (49/87). PFS at 1 year was 37%, 41%, 83 % and 75.5% respectively (Table 1).

Conclusion:

Our study demonstrated that a low Haemoglobin level pre- and during treatment was an independent poor prognostic factor leading to higher pelvic and non-pelvic relapse rates. It highlights the importance of maintaining Hb level above at least 110 g/l by means of transfusion of packed red blood cells. The most effective transfusion threshold requires further investigation and may not be above 120 g/l as suggested by some guidance (RCR 2019). Pre-treatment haemoglobin levels are significantly correlated with survival and local control, perhaps a potential biomarker for prognosis. Further studies are required to investigate this hypothesis.